Latest News on MRNA

Financial News Based On Company


Advertisement
Advertisement

Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?

https://www.tradingview.com/news/zacks:78d07d93f094b:0-moderna-can-the-vaccine-business-fund-its-next-phase-of-growth/
Moderna reported strong Q3 2026 results and raised its full-year revenue guidance, but concerns emerged after its Analyst Day regarding future spending commitments, particularly in oncology, without clear corresponding multi-year revenue projections. The company aims to diversify beyond COVID-19 vaccines by expanding its respiratory and oncology pipelines, despite facing stiff competition. Moderna's stock has significantly outperformed the industry year-to-date, though it trades at a premium valuation.

Options Bulls Target Dollar Tree Stock Ahead of Earnings

https://www.schaeffersresearch.com/content/analysis/2026/11/19/options-bulls-target-dollar-tree-stock-ahead-of-earnings
Options traders are showing significant optimism for Dollar Tree (DLTR) stock ahead of its third-quarter earnings report on Tuesday, November 24. Despite a mixed post-earnings history and a recent choppy trading pattern, the stock is near two-year highs, and its 10-day call/put volume ratio is in the 96th percentile of its annual range, indicating strong bullish sentiment. Analysts estimate earnings of 89 cents per share on $5.05 billion in revenue.

Evotec, Bristol Myers Squibb Advance Second Molecular Glue Drug to Clinic

https://www.contractpharma.com/breaking-news/evotec-bristol-myers-squibb-advance-second-molecular-glue-drug-to-clinic/
Evotec and Bristol Myers Squibb have achieved another significant milestone in their protein degradation collaboration with the FDA's acceptance of an Investigational New Drug (IND) application for a second molecular glue drug candidate. This cereblon E3 ligase modulator (CELMoD) is expected to begin Phase 1 clinical testing in 2027, building on the success of their first candidate which entered Phase 1 in March 2026. The partnership, which began in 2018, leverages Evotec's advanced screening and AI capabilities with Bristol Myers Squibb's CELMoD library to develop novel therapeutics for oncology and other diseases.

Moderna Just Dropped 17% in a Week as 2027 Cash Costs Head to $4 Billion. Time to Sell, or Load Up?

https://www.tikr.com/pt/blog/moderna-just-dropped-17-in-a-week-as-2027-cash-costs-head-to-4-billion-time-to-sell-or-load-up
Moderna's stock recently dropped 17% after the company guided towards $4 billion in cash costs for 2027, and up to $4.5 billion annually through 2030, largely for cancer drug development including its melanoma vaccine with Merck. This substantial spending raises concerns as analysts' 2028 revenue estimates for Moderna are currently below these projected costs. The article suggests that at 37x forward sales, the stock might be overvalued given the unfiled product launch and increasing expenditures.

Moderna president Stephen Hoge sells $16.9M in stock

https://www.investing.com/news/insider-trading-news/moderna-president-stephen-hoge-sells-169m-in-stock-93CH-5038145
Moderna President Stephen Hoge sold approximately $16.9 million worth of company stock and acquired $1.87 million through option exercises on November 16 and 17, 2026. These transactions, made under a pre-arranged trading plan, occurred as Moderna's stock saw a nearly 15% decline in the past week, despite a 714% increase over the past year. InvestingPro analysis indicates the stock is currently overvalued, while the company recently reported a swing to profit in Q3 2026 and revised its revenue guidance upwards.
Advertisement

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

https://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/8909526/moderna-s-cancer-vaccine-worked-and-the-stock-plunged-anyway-here-s-what-investors-are-missing/
Moderna's personalized melanoma vaccine, developed with Merck, showed promising Phase 3 results, reducing cancer recurrence or death by 42%. Despite this, Moderna's stock fell due to high market expectations and an early leak of results. Analysts later softened their views, recognizing the vaccine's meaningful improvement and potential beyond melanoma, including in pancreatic cancer, suggesting investors might be overlooking a broader opportunity.

Medirom Healthcare Technologies Files 20-F Annual Report for Fiscal Year Ending December 31, 2025

https://kalkinemedia.com/us/news/announcements/medirom-healthcare-technologies-files-20-f-annual-report-for-fiscal-year-ending-december-31-2025
Medirom Healthcare Technologies Inc. (NASDAQ:MRM) filed its annual Form 20-F report with the SEC for the fiscal year ending December 31, 2025. The report details 7,901,950 common shares outstanding, the company's non-accelerated filer status, and adherence to U.S. GAAP. Medirom, incorporated in Japan, operates salon-related services and emphasizes its Digital Preventative Healthcare Segment for continued growth and profitability.

Should Vaccine Medium Launch Require Action From Thermo Fisher Scientific (TMO) Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-vaccine-medium-launch-require-action-from-thermo-fish
Thermo Fisher Scientific recently launched Gibco VaxEvo CD 293 Medium, a new solution for adenovirus vaccine production. While this product supports the company's focus on pharma and biotech customers and bioproduction, analysts view it as an incremental development rather than a major factor for near-term results. The company's investment narrative continues to depend on the recovery of funding-sensitive customers and effective portfolio reshaping, alongside its consistent dividend payouts and strategic M&A activities.

MVB Financial Announces $0.17 Quarterly Dividend for Q4 2026

https://kalkinemedia.com/us/news/announcements/mvb-financial-announces-017-quarterly-dividend-for-q4-2026
MVB Financial Corp. (NASDAQ:MVBF) has declared a quarterly cash dividend of $0.17 per share for the fourth quarter of 2026, consistent with the previous quarter's payout. The dividend will be paid on December 15, 2026, to shareholders of record as of December 1, 2026. This announcement was made via a Form 8-K filing on November 18, 2026.

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

https://www.tradingview.com/news/zacks:d54a2d82c094b:0-merck-ends-nemtabrutinib-development-what-s-next-for-its-pipeline/
Merck has discontinued the development of nemtabrutinib (MK-1026), an investigational Bruton's tyrosine kinase inhibitor for hematologic malignancies, after a review indicated its potential benefits might not outweigh the risks. Despite this setback, Merck's broader pipeline, particularly in oncology, vaccines, and infectious diseases, remains promising, with several late-stage candidates and an expectation of launching 20 new drugs by 2030. The company anticipates over $70 billion in non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double Keytruda's peak sales estimate.
Advertisement

Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

https://finance.yahoo.com/healthcare/articles/moderna-targets-end-cancer-therapy-131303838.html
Moderna and Merck anticipate filing a U.S. application for their individualized cancer therapy, intismeran, by the end of the year, following positive Phase III melanoma results. Moderna views this therapy as a multibillion-dollar opportunity, estimating 22,000 U.S. patients could be eligible for adjuvant melanoma treatment. The company also expects further trial results for kidney and bladder cancer in the coming years and plans to leverage its strong balance sheet to support oncology development.

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

https://www.streetinsider.com/Business+Wire/Thermo+Fisher+Scientific+Launches+Gibco%E2%84%A2+VaxEvo%E2%84%A2+CD+293+Medium+to+Advance+Adenovirus+Vaccine+Production/27367292.html
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium. This product is designed to enhance suspension HEK293 cell growth and high-titer adenovirus production, crucial for vaccine development and manufacturing. It aims to simplify upstream workflows and improve productivity for human and animal health vaccine developers.

Moderna drops marking longest losing streak since 2024

https://seekingalpha.com/news/4674321-moderna-stock-longest-losing-streak-since-2024
Moderna (MRNA) stock experienced its longest losing streak since November 2024, trading lower for seven consecutive sessions. This decline follows analysts issuing bearish views on the stock after its significant year-to-date rally of nearly 600%.

Analysts Offer Insights on Healthcare Companies: Kardigan, Inc. (KARD), Moderna (MRNA) and Revvity (RVTY)

https://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/8877776/analysts-offer-insights-on-healthcare-companies-kardigan-inc-kard-moderna-mrna-and-revvity-rvty/
This article provides an overview of recent analyst ratings for three healthcare companies: Kardigan, Inc. (KARD), Moderna (MRNA), and Revvity (RVTY). Cantor Fitzgerald maintained a Buy rating on Kardigan with a $50 price target, while Goldman Sachs maintained a Hold on Moderna with a $195 price target. Stifel Nicolaus maintained a Hold rating on Revvity with a $177 price target.

Emergent Biosolutions teams with Asimov to advance antibody candidate pipeline

https://tradersunion.com/news/companies/show/4285880-emergent-asimov-antibodies/
Emergent Biosolutions has partnered with Asimov to accelerate the development of innovative antibody candidates. This collaboration aims to bolster preparedness against evolving biological threats by advancing novel antibody research to enhance protection and support public health defense. This partnership builds on Emergent's recent contract modification with the U.S. Department of War to supply medical products.
Advertisement

Veru presents data on enobosarm for obesity treatment

https://www.investing.com/news/company-news/veru-presents-data-on-enobosarm-for-obesity-treatment-93CH-5033022
Veru Inc. presented new data from a post hoc analysis of its Phase 2b QUALITY study at ObesityWeek 2026, demonstrating that enobosarm 3mg combined with semaglutide helped elderly obese patients preserve lean muscle mass and improve physical function compared to semaglutide alone. Patients receiving enobosarm gained 0.3 kg of lean mass, while the placebo group lost 2.0 kg. The company is currently evaluating enobosarm in its Phase 2b PLATEAU clinical trial, with interim results expected in Q1 2027.

JPMorgan raises Moderna stock price target on expense outlook

https://www.investing.com/news/analyst-ratings/jpmorgan-raises-moderna-stock-price-target-on-expense-outlook-93CH-5032651
JPMorgan has increased its price target for Moderna Inc. to $102 from $77, while maintaining an Underweight rating. This adjustment follows Moderna's updated 2026 guidance and its expense framework for 2027 and beyond, with JPMorgan noting the company's balanced expense outlook and healthier cash balance supporting oncology investments. Despite the raised price target, the Underweight rating persists due to a perceived valuation disconnect between Moderna's market capitalization and its pipeline.

Teva Pharmaceutical Industries (TEVA) Could Be 13% Undervalued Following FDA Approval For IGALMI

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-13-undervalued
Teva Pharmaceutical Industries recently received FDA approval for at-home use of IGALMI, a sublingual film for agitation in mental health conditions. Analysts at Simply Wall St believe the stock is 13% undervalued, with a fair value of $48.94 compared to its current trading price of $42.57. This valuation is based on expected profit growth from Teva's shift towards higher-value branded CNS drugs, though it depends on successful product launches and avoiding pipeline setbacks.

Moderna, Inc. Stock 12‑Month Price Target Raised to $162.84, Implies 24% Downside

https://www.tradingview.com/news/tradingview:6a33e3288eb4a:0-moderna-inc-stock-12-month-price-target-raised-to-162-84-implies-24-downside/
Moderna, Inc.'s average 12-month price target has been raised to $162.84 by 19 analysts, implying a potential 24% downside from its recent closing price. Despite the increased target, the consensus rating among 27 covering analysts remains "Hold," with a breakdown of 5 Buys, 16 Holds, and 6 Sells. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.

At $215, Moderna Stock Already Prices In A Comeback

https://www.trefis.com/stock/mrna/articles/625594/at-215-moderna-stock-already-prices-in-a-comeback/2026-11-17
Moderna (MRNA) stock at $215.27 is trading at a valuation that already assumes a significant comeback, with analysts forecasting substantial revenue growth and a return to profitability by 2029. Despite a recent strong performance, the current price reflects optimistic 2030 earnings and revenue estimates that may be challenging to beat. The company's pipeline and balance sheet offer a bull case, but past volatility and current cash burn present risks.
Advertisement

Lexeo’s LX2020 Earns RMAT Designation for PKP2 Cardiomyopathy

https://www.clinicaltrialvanguard.com/news/lexeos-lx2020-earns-rmat-designation-for-pkp2-cardiomyopathy/
Lexeo Therapeutics' LX2020 has received RMAT designation from the FDA for PKP2 cardiomyopathy, based on positive interim data from its Phase I/II trial. This designation indicates the therapy may offer substantial improvement over existing options for this serious condition and will lead to closer FDA collaboration and a potential expedited review. The trial has successfully dosed a majority of participants at the higher, therapeutic dose level, establishing a credible safety database for regulatory discussions.

Flagship Pioneering Puts £100 Million Into First Overseas Lab, Betting on AI Drug Discovery in London

https://finance.biggo.com/news/038e32c1-f578-4c48-8f66-d614eaeccf8d
Flagship Pioneering is investing an initial £100 million (about $131.9 million) to open its first company-creation lab outside the U.S. in London. The Flagship Origination Lab, U.K. will focus on building AI-native biotech companies, leveraging National Health Service patient data, and aims to attract an additional £500 million from partners. This move marks a significant expansion for the venture firm, which has previously operated solely from the U.S. and notably launched Moderna.

Precision Optics Corporation, Inc. (POCI) Tops Q3 EPS by 3c ; Offers Guidance

https://www.streetinsider.com/Earnings/Precision+Optics+Corporation%2C+Inc.+%28POCI%29+Tops+Q3+EPS+by+3c+%3B+Offers+Guidance/27358153.html
Precision Optics Corporation, Inc. (POCI) reported a Q3 EPS of ($0.04), exceeding analyst estimates by $0.03, and revenue of $8.15 million, surpassing the consensus of $7.9 million. The company also provided FY2026 revenue guidance of $30-33 million, aligning with analyst expectations.

Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data

https://biotechdispatch.com.au/news/radiopharm-brain-metastases-imaging-agent-closely-matches-mri-in-interim-phase-2b-data
Radiopharm Theranostics has released interim results from a Phase 2b study of its imaging agent RAD101, which showed 93.5% agreement with contrast-enhanced MRI for detecting recurrent brain metastases. The company plans to advance RAD101 toward a pivotal trial in the US, having already secured Fast Track designation from the FDA and a manufacturing partnership with Siemens Healthineers. This agent targets fatty acid metabolism, aiming to provide a more accurate diagnostic tool for patients with brain metastases.

Is Moderna's Cancer Vaccine a Game Changer for the Stock?

https://www.theglobeandmail.com/investing/markets/stocks/MRNA-Q/pressreleases/8864049/is-moderna-s-cancer-vaccine-a-game-changer-for-the-stock/
Moderna's stock has surged over 600% this year due to positive clinical trial results for its cancer vaccine, intismeran, when combined with Merck's Keytruda, showing significant effectiveness against melanoma. While the vaccine is highly effective and appears likely for approval, the article cautions that the stock's valuation might be overly inflated, potentially pricing in unconfirmed applications for other cancers and overlooking challenges related to personalized vaccine production at scale and profit-sharing with Merck. Investors are advised against buying the stock at its current "unsustainable level" due to significant downside risk.
Advertisement

Is Moderna's Cancer Vaccine a Game Changer for the Stock?

https://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/8864048/is-modernas-cancer-vaccine-a-game-changer-for-the-stock/
Moderna's stock has surged over 600% this year due to promising Phase 3 clinical trial results for its cancer vaccine, intismeran, when combined with Merck's Keytruda for melanoma patients. While the treatment significantly reduced the risk of death and cancer recurrence, the article cautions that the stock's valuation may be inflated by speculation, as the vaccine is not yet approved and faces challenges with large-scale personalized production. Investors are advised against buying Moderna at its current high price due to potential downside risk.

Forge Nano Reports Third Quarter 2026 Results; Raises Over $130 Million; Reiterates Guidance

https://www.tradingview.com/news/financewire:f0f79ffa0094b:0-forge-nano-reports-third-quarter-2026-results-raises-over-130-million-reiterates-guidance/
Forge Nano (NANO) reported its third-quarter 2026 financial and operating results, highlighting a successful Nasdaq listing on October 22, 2026, which raised over $130 million. The company also announced significant strategic milestones, including breaking ground on America's Battery Gigafactory, expanding semiconductor equipment manufacturing, and acquiring HZO to bolster its coatings solutions business. Furthermore, Forge Nano expanded into the pharmaceuticals sector through a joint development agreement with Nanexa for its PharmaShell® platform.

Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive

https://247wallst.com/investing/2026/11/16/moderna-is-up-over-600-this-year-heres-what-jim-cramer-learned-in-his-exclusive/
Moderna's stock has surged over 600% this year, largely due to promising melanoma data showing its personalized cancer shot, combined with Merck's Keytruda, reduced the risk of recurrence or death by 42%. CEO Stéphane Bancel expects to file with the FDA before year-end for a 2027 launch. While the stock's valuation already reflects much of this excitement, upcoming catalysts like kidney cancer data and current vaccine sales are funding further cancer research, though risks like heavy reliance on COVID vaccines and debt remain.

Forge Nano Reports Third Quarter 2026 Results; Raises Over $130 Million; Reiterates Guidance

https://markets.businessinsider.com/news/stocks/forge-nano-reports-third-quarter-2026-results-raises-over-130-million-reiterates-guidance-1036768819
Forge Nano Holdings, Inc. announced its financial and operating results for the third quarter ended September 30, 2026, highlighting significant commercial and strategic milestones including its Nasdaq listing under the ticker “NANO” and raising over $130 million. The company also detailed its expansion into pharmaceuticals via a joint development agreement with Nanexa and the acquisition of HZO to consolidate its coatings solutions business. Forge Nano reiterated its 2026 financial guidance, projecting $18 million in revenue, $12.7 million in government grant income, and $9.4 million from HZO.

Leqembi Five-Year Data at CTAD Alzheimer's Meeting Tonight: Control Group Moves Benefit 0.42 Points

https://www.techtimes.com/articles/330819/20261116/leqembi-five-year-data-ctad-alzheimers-meeting-tonight-control-group-moves-benefit-042-points.htm
Five-year data for lecanemab (Leqembi), an Alzheimer's antibody, are being presented at the CTAD conference. The long-term efficacy is being evaluated against external control groups, as the original trial's placebo participants switched to lecanemab, removing a direct comparison. The reported four-year benefit on the Clinical Dementia Rating Sum of Boxes (CDR-SB) varies depending on the control group used, highlighting the complexities of assessing long-term drug effectiveness without a sustained placebo arm.
Advertisement

Raymond James reiterates Tvardi Therapeutics stock rating on HCC data By Investing.com

https://ca.investing.com/news/stock-market-news/raymond-james-reiterates-tvardi-therapeutics-stock-rating-on-hcc-data-93CH-4960517
Raymond James has reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics Inc (NASDAQ:TVRD) after the company's Q3 2026 earnings, citing promising early data for TTI-101 in hepatocellular carcinoma (HCC) and the tolerability of TTI-109. The price target suggests significant upside from the current stock price of $1.18, despite a 73% year-to-date decline. The firm noted Tvardi's strong balance sheet and views the upcoming HCC readout and TTI-109's advancement into ulcerative colitis as key opportunities.

A co-founder of five biotech companies will join the 12-member board at Bruker (BRKR).

https://www.stocktitan.net/sec-filings/BRKR/8-k-bruker-corp-reports-material-event-919df485e6e3.html
Bruker Corporation (BRKR) announced the appointment of Eicke Latz, MD, PhD, an internationally recognized medical institute director and biopharma entrepreneur, to its board of directors, effective January 1, 2027. Latz has co-founded five biotechnology companies and is currently the Scientific Director of the German Rheumatology Research Center. The board's expansion to 12 directors coincides with Bruker's strategic focus on post-genomic life-science tools and molecular diagnostics.

Flagship's Afeyan Sees UK Bet Creating Next Moderna

https://ca.finance.yahoo.com/video/flagships-afeyan-sees-uk-bet-113516829.html
Noubar Afeyan, founder and CEO of Flagship Pioneering and co-founder of Moderna, has established the firm's first full-scale company-creation operation outside the US in the UK. He anticipates this new investment could reach £600 million relatively soon. Afeyan discussed the reasons for choosing the UK, the role of AI in accelerating drug discovery and biotech creation, and the need for safeguards for autonomous AI agents.

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

https://www.investing.com/news/stock-market-news/jj-in-talks-to-buy-eye-disease-biotech-ollin-for-34-bln-ft-reports-5028255
Johnson & Johnson is reportedly in advanced discussions to acquire Ollin Biosciences, a privately held eye disease drug developer, for up to $3.4 billion. The deal is expected to include an upfront payment of $2.2 billion and up to $1.2 billion in milestone payments, aiming to expand J&J's presence in the retinal disease treatment market. Ollin Biosciences is currently developing OLN324, a drug for wet age-related macular degeneration and diabetic macular oedema, which is anticipated to enter late-stage clinical trials.

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

https://www.prnewswire.com/news-releases/viking-therapeutics-highlights-clinical-data-from-vk2735-obesity-program-at-obesityweek-2026-302939732.html
Viking Therapeutics announced new clinical data from its VK2735 obesity program were highlighted at ObesityWeek® 2026. An exploratory analysis of the Phase 2 VENTURE trial showed that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, alongside improvements in multiple cardiometabolic markers. The company also presented baseline characteristics from the ongoing Phase 3 VANQUISH-2 study, which is evaluating subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes.
Advertisement

Alvotech (NASDAQ:ALVO) Stock Moved Up to Hold by Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-alvotech-nasdaq-alvo-stock-moved-up-to-hold-by-wall-street-zen-2026-11-15/
Wall Street Zen upgraded Alvotech (NASDAQ:ALVO) from a "sell" to a "hold" rating on Sunday, November 15, 2026. This comes amidst mixed analyst sentiment, with MarketBeat reporting an average "hold" rating and a $8.40 consensus price target for the company. Despite reporting a quarterly loss in line with expectations, Alvotech's revenue of $111.6 million fell below analysts' forecasts.

Moderna president Stephen Hoge sells $11.7M in common stock

https://www.investing.com/news/insider-trading-news/moderna-president-stephen-hoge-sells-117m-in-common-stock-93CH-5027738
Moderna president Stephen Hoge sold approximately $11.7 million in common stock in mid-September, following the exercise of stock options worth about $1.9 million. These transactions, executed under a Rule 10b5-1 trading plan, occurred while Moderna shares were down 12% over the past week but up 802% over the last year, with the stock currently appearing overvalued. Hoge now directly holds over 1.5 million shares and 305,810 stock options, with additional indirect beneficial ownership.

Moderna RSV Shot 82% Effective Against Hospitalization in Veterans 50 and Older, but Infection Protection Fell With Age

https://www.medicaldaily.com/moderna-mresvia-rsv-vaccine-veterans-82-percent-hospitalization-481250
A large Veterans Affairs study found Moderna's mRNA RSV vaccine (mResvia) was 81.8% effective at preventing RSV-related hospitalization in veterans aged 50 and older, and 60.3% effective against documented infection. However, protection against infection significantly decreased with age, dropping from 82.9% in those 50-59 to 28.6% in veterans 80 and older. The CDC recommends a single dose for all adults 75 and older and for those 50-74 at increased risk of severe RSV.

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

https://www.fool.com/coverage/better-buy/2026/11/14/axsome-therapeutics-vs-moderna-which-biotech-innovator-stock-is-a-better-buy-for-2027/
This article compares Axsome Therapeutics and Moderna, analyzing their financial performance, growth prospects, and risk profiles to determine which is a better investment for 2027. Axsome, focused on CNS treatments, shows strong revenue growth and is narrowing losses, while Moderna, an mRNA technology leader, is diversifying its pipeline but faces significant net losses and intense competition. The author concludes that Axsome is the better buy due to its more conservative valuation and strong near-term revenue growth despite Moderna's revolutionary mRNA potential.

Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow

https://seekingalpha.com/article/4968001-moderna-inc-mrna-analyst-investor-day-slideshow?source=feed_all_articles
Moderna, Inc. (MRNA) published a slide deck for its Analyst/Investor Day on November 13, 2026. This article provides access to the slideshow in conjunction with the event, following the company's recent Q3 earnings report where it beat EPS and revenue estimates.
Advertisement

Cellectis could cut 70% of workforce in shift to in vivo therapies

https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies
Cellectis announced a potential global workforce reduction of up to 70%, affecting around 160 employees, as it transitions from allogeneic CAR T cell therapies to focus on in vivo gene editing. The company has halted enrollment in its CAR T programs to concentrate on its HEAL-101 and HEAL-201 in vivo candidates, which target severe hypertriglyceridemia and hypercholesterolemia, respectively. This strategic shift is expected to fund operations into the second half of 2028 and deliver initial clinical data for its in vivo programs in 2027 and 2028.

Valneva shares fall 2.5% and drop back below their MM50, near the bottom of the SBF 120

https://www.ideal-investisseur.fr/en/stock-news/valneva-shares-fall-2-5-and-drop-back-below-their-mm50-near-the-bottom-of-the-sbf-120/29343.html
Valneva shares declined by 2.43% to €2.57, placing the Lyon-based vaccine laboratory among the weakest performers in the SBF 120 index. This fall brings the stock below its MM50, erasing recent rebound gains, despite ongoing positive news regarding its vaccine developments. The stock remains near a neutral RSI at 51, with support at €2.33 and resistance at €2.68.

Surrozen prices $60 million stock offering at $31.67 per share

https://scanx.trade/stock-market-news/ipo/surrozen-prices-60-million-stock-offering-31-67-per-share/56123050
Surrozen has priced an underwritten offering of 1,894,540 shares of its common stock at $31.67 per share, aiming to raise $60 million in gross proceeds. The biotechnology company, specializing in Wnt signaling therapeutics for ophthalmic conditions, expects the offering to close around November 16, 2026, with participation from major life sciences investors. Morgan Stanley, Guggenheim Securities, and Cantor are acting as joint book-running managers for the transaction.

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/8824203/moderna-issues-cost-outlook-amid-revenue-uncertainty-stock-falls/
Moderna's shares fell after its 2026 Analyst Day, where it outlined a cost outlook for 2027 and beyond, but provided limited visibility into future revenue growth. While oncology, particularly its personalized cancer therapy intismeran autogene with Merck, is highlighted as a key long-term growth driver, investors were concerned by the projected spending without a clear revenue forecast. The company also continues to expand its infectious disease vaccine portfolio and expects 2026 revenues to grow 15-25%.

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

https://www.theglobeandmail.com/investing/markets/stocks/SNY/pressreleases/8824203/moderna-issues-cost-outlook-amid-revenue-uncertainty-stock-falls/
Moderna's shares fell after its 2026 Analyst Day, where the company highlighted oncology as a key long-term growth opportunity and outlined cost expectations for 2027 through 2030, but provided limited visibility into future revenue growth. The company is advancing a personalized cancer therapy with Merck and expanding its infectious disease vaccine portfolio. Despite a projected 15-25% revenue growth for 2026, investors were concerned about the lack of specific revenue forecasts for subsequent years amidst significant planned investments in oncology.
Advertisement

Immunic shares fall 5% on third quarter earnings miss

https://www.investing.com/news/earnings/immunic-shares-fall-5-on-third-quarter-earnings-miss-5024923
Immunic Inc. (NASDAQ:IMUX) reported a third-quarter loss per share of -$0.99, missing analyst estimates by $0.05, leading to a 5.44% drop in shares during pre-market trading. The biotechnology company's net loss increased to $42.3 million from $25.6 million in the prior year, primarily due to higher operating expenses driven by personnel costs and NDA readiness activities. Despite the earnings miss, the company expects cash reserves to fund operations into late 2027 and remains on track to release top-line data from its Phase 3 ENSURE trials in December 2026.

Moderna's chief legal officer to retire in March 2027

https://www.streetinsider.com/Corporate+News/Modernas+chief+legal+officer+to+retire+in+March+2027/27344022.html
Moderna announced that Shannon Thyme Klinger, its Chief Legal Officer, will retire on March 31, 2027, under a Transitional Services and Retirement Agreement. She will continue in her role, receiving salary and benefits, and will be eligible for a 2026 performance bonus. The agreement also includes severance payments and potential litigation-contingent bonuses related to ongoing lawsuits.

Sensus Healthcare earnings matched, revenue fell short of estimates

https://www.investing.com/news/earnings/sensus-healthcare-earnings-matched-revenue-fell-short-of-estimates-5023693
Sensus Healthcare (NASDAQ: SRTS) reported third-quarter EPS of $-0.090, meeting analyst estimates, but its revenue of $6M fell short of the consensus estimate of $6.23M. The company's stock price has risen 12.590% in the last three months but is down -27.800% over the last 12 months. InvestingPro rates Sensus Healthcare's financial health as "fair performance."

Azitra, Inc. (AZTR) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/AZTR/
Azitra, Inc. (AZTR) is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology. The company's stock shows significant volatility and negative returns across various timeframes, with a current price of $0.6685. Azitra is currently developing several treatments for skin diseases, including ATR-04 for cancer patient rash, ATR-12 for Netherton syndrome, and ATR-01 for ichthyosis vulgaris, and has a joint development agreement with Bayer.

Moderna falls 7% on the day it gave a roughly $4 billion 2027 cash cost target

https://www.quantisnow.com/articles/moderna-falls-7-on-analyst-day-as-4-billion-cost-plan-lands-without-2027-revenue-guide
Moderna's stock fell 6.97% after its 2026 analyst day where it provided a 2027 cash cost target of about $4 billion, exceeding the midpoint of its previous guidance, and no 2027 revenue forecast. This increase in expected spending, particularly for oncology investments, raised concerns among investors. Despite the drop, the article notes that trading volume was light, suggesting potential profit-taking or broader weakness in vaccine stocks rather than a heavy sell-off due to cost shock.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement